MAPT and mild neurocognitive disorder: Our cellular and animal model data further support the hypothesis that PROG acts directly by modulating the levels of the two key pathological molecules, TDP-43 and Tau, and thus could be a viable therapeutic target for subgroups of FTD, as has been proposed for MND.